Shanghai Pharmaceuticals (601607) Board of Directors approved multiple proposals for 2025, planning to distribute a cash dividend of 1.743 billion yuan.

China Visit Net data Shanghai Pharmaceutical Group Co., Ltd. held the 29th meeting of the Eighth Session of its Board of Directors on March 30, 2026, and approved several important resolutions. The core financial figures show that the company’s net profit attributable to shareholders of listed companies for 2025 was approximately RMB 5.725 billion. The Board of Directors approved the 2025 profit distribution proposal. It proposes to use a total share capital of approximately 3.708 billion shares as the base, and to distribute to all shareholders a cash dividend of RMB 3.50 per 10 shares (including tax). In addition to the cash dividends already distributed for the first half of 2025, the total cash dividends distributed for 2025 are expected to be approximately RMB 1.743 billion, accounting for 30.45% of the net profit attributable to shareholders of listed companies in the consolidated statement for the same period. This profit distribution proposal still needs to be submitted to the shareholders’ meeting for consideration.

At the same time, the meeting approved multiple annual operating and financing plans. Among them, resolutions including 2026 annual ordinary related-party transactions, an external guarantee plan (total额度 equivalent to approximately RMB 12.826 billion), bank credit facilities (no more than the equivalent of RMB 10 billion), and the issuance of debt financing instruments (outstanding balance no more than the equivalent of RMB 15 billion), among others, were approved. The company plans to carry out financial derivative business in 2026, with an amount not exceeding USD 1.075 billion or the equivalent in other currencies. In addition, the Board of Directors agreed to reappoint Deloitte Huayong Certified Public Accountants LLP as the company’s audit institution for 2026, and approved routine resolutions such as the “2025 Annual Report and Summary” and the “2025 Annual Board of Directors Work Report.” It is worth noting that when reviewing the profit distribution proposal, two directors voted against it, on the grounds that the proportion of cash dividends to net profit is relatively low. All resolutions that require approval by the shareholders’ meeting will be submitted for deliberation at a subsequently convened shareholders’ meeting.

Huge amounts of information and precise interpretation—available on the Sina Finance app